# EU-1-14-979_public-assessment-report_20150213_20150213_ofev-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
MEDICINES
SCIENCE
HEALTH
20 November 2014
EMA/76777/2015
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Ofev
International non-proprietary name: nintedanib
Procedure No. EMEA/H/C/003821/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
30 Churchill Place . Canary Wharf . London E14 5EU . United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
Table of contents
1. Background information on the procedure
6
1.1. Submission of the dossier
6
7
1.2. Manufacturers.
1.3. Steps taken for the assessment of the product.
7
2. Scientific discussion
9
2.1. Introduction.
9
2.2. Quality aspects
12
2.2.1. Introduction
12
2.2.2. Active Substance
12
2.2.3. Finished Medicinal Product
14
2.2.4. Discussion on chemical, pharmaceutical and biological aspects
16
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
16
2.3. Non-clinical aspects
16
2.3.1. Introduction.
16
2.3.2. Pharmacology
16
2.3.3. Pharmacokinetics
23
2.3.4. Toxicology
26
2.3.5. Ecotoxicity/environmental risk assessment
40
2.3.6. Discussion on non-clinical aspects.
41
2.3.7. Conclusion on the non-clinical aspects
46
2.4. Clinical aspects
47
2.4.1. Introduction
47
2.4.2. Pharmacokinetics.
50
2.4.3. Pharmacodynamics
54
2.4.4. Discussion on clinical pharmacology.
55
2.4.5. Conclusions on clinical pharmacology
57
2.5. Clinical efficacy
57
2.5.1. Dose response studies.
57
2.5.2. Main studies
58
2.1. Supportive study
66
2.1.1. Discussion on clinical efficacy
68
2.1.2. Conclusions on the clinical efficacy.
69
2.2. Clinical safety
69
2.2.1. Discussion on clinical safety
77
2.2.2. Conclusions on the clinical safety
78
2.3. Pharmacovigilance.
78
2.4. Risk Management Plan
78
2.5. Product information
81
2.5.1. User consultation
81
3. Benefit-Risk Balance.
Benefits
82
82
Beneficial effects
82
Uncertainty in the knowledge about the beneficial effects
82
Risks
82
Assessment report
EMA/76777/2015
Page 2/85
